This study is testing a new treatment called TUB-040 for people with ovarian cancer or non-small cell lung cancer that has come back or hasn't responded to other treatments. TUB-040 is an antibody-drug conjugate, which means it's designed to deliver a cancer-fighting drug directly to tumor cells that have a specific marker called NaPi2b. The main goal is to find the safest and most effective dose of TUB-040. You might be able to join if you are 18 or older, your cancer can't be cured with current treatments, and you've already tried standard treatments. The study is currently unclear on its recruitment status and plans to enroll about 250 people.

Study design

This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It involves two parts: first, increasing doses of TUB-040 are given to find the highest safe dose, then different doses are compared to find the best one.

What's involved

TUB-040 is given as an intravenous (IV) solution on day 1 of each 21-day treatment cycle.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from enrollment until 30 days after your last study drug dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.